Table 3.

Sensitivity analysis results: Incremental cost-effectiveness ratios for HCV infant testing strategies versus HCV RNA testing at 2–6 months for infants with known exposure, by proportion of pregnant persons that are screened for HCV infection, United States, 2022

	Strategy (reference=Known exposure: HCV RNA test at 2–6 months)
Proportion of pregnant persons screened for HCV	Known exposure: Anti-HCV with reflex to HCV RNA at 18 months (Test Strategy 1)	Universal testing: Anti-HCV with reflex to HCV RNA at 18 months (Test Strategy 2)	Universal testing: HCV RNA test at 2–6 months (Test Strategy 3)
0.50	More expensive, fewer QALYS	129,476	53,665
0.55	More expensive, fewer QALYS	569,548	59,532
0.60	More expensive, fewer QALYS	More expensive, fewer QALYS	67,746
0.65	More expensive, fewer QALYS	More expensive, fewer QALYS	76,727
0.70	More expensive, fewer QALYS	More expensive, fewer QALYS	92,427
0.75	More expensive, fewer QALYS	More expensive, fewer QALYS	113,463
0.80	More expensive, fewer QALYS	More expensive, fewer QALYS	139,075
0.85	More expensive, fewer QALYS	More expensive, fewer QALYS	197,018
0.90	More expensive, fewer QALYS	More expensive, fewer QALYS	292,229
0.95	More expensive, fewer QALYS	More expensive, fewer QALYS	661,659

Notes: The reference strategy is HCV RNA testing at 2–6 months among infants with known exposure. Assumes 43.0% of infants born to HCV RNA+ pregnant persons attend an 18-month visit. Assumes 73.5% of infants born to HCV RNA+ pregnant persons attend a 2–6 month visit. Assumes 75.0% of infants born to pregnant persons without HCV attend an 18-month visit. Assumes 85.0% of infants born to pregnant persons without HCV attend a 2–6 month visit.